Nektar raises new $125m debt to clean out old debt and focus on asset progress
This article was originally published in Scrip
Nektar Therapeutics closed the private placement of $125 million in senior secured notes on 11 July, which will help the San Francisco-based company pay off a debt due in September and hold firm on its commitment to advance one preclinical asset per year into the clinic.
You may also be interested in...
Amgen’s R&D programs are vitally important as sales of multiple blockbusters continue to drop, but one major late-stage asset had disappointing results and another key drug has an aggressive competitor.
The company has assembled small molecule discovery capabilities for the development of targeted cancer drugs that it believes rivals big pharma efforts and will fulfill patients’ unmet needs.
Public Company Edition: Four health care special purpose acquisition vehicles went public and two others announced mergers, but only one biopharma firm priced an IPO during the week of 19-23 October. Replimune’s $250m offering led recent FOPOs.